Trump Drug Pricing Flaw & Gilead Deal: What to Know
A structural gap in Trump's most-favored nation drug pricing framework raises doubts, while Gilead Sciences makes a major autoimmune therapeutics acquisition.
By Robert Kim
2 articles tagged "CMS"
A structural gap in Trump's most-favored nation drug pricing framework raises doubts, while Gilead Sciences makes a major autoimmune therapeutics acquisition.
CMS administrator Chris Klomp clarified TrumpRx targets the uninsured, not most Americans, countering President Trump's broader claims about the drug discount platform.